Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04166045 · ClinicalTrials.gov registry record · NA

Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain

A NA study, sponsored by Theranova, L.L.C..

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT04166045 is a NA study that has completed, run by Theranova, L.L.C.. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04166045, a NA study, has completed, sponsored by Theranova, L.L.C..

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

Clinical study to determine the responder rate of the TheraNova Migraine Treatment System to that of a sham control treatment.

Interventions

  • DEVICE Sham Treatment Location
  • DEVICE Verum Treatment Location

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2020-06-12
Est. Completion 2021-04-29
Phase NA

Sponsor

Theranova, L.L.C.

11 total trials

What the Registry Record Tells You About NCT04166045

The ClinicalTrials.gov registry entry for NCT04166045 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranova, L.L.C., which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Sham Treatment Location is the first listed.

NCT04166045 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04166045 about?

NCT04166045 is a clinical study titled "Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain". Clinical study to determine the responder rate of the TheraNova Migraine Treatment System to that of a sham control treatment.

What is the current status of trial NCT04166045?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2020-06-12. Estimated completion is 2021-04-29.

What interventions are being tested in trial NCT04166045?

The interventions under investigation include: Sham Treatment Location (DEVICE), Verum Treatment Location (DEVICE).

Who is sponsoring clinical trial NCT04166045?

This trial is sponsored by Theranova, L.L.C., which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.